COX-2, NSAIDs, and cardiovascular risk

Patricia McGettigan, David Henry

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Clinical studies of selective and nonselective inhibitors of cyclooxygenase-2 (COX-2) provide evidence that inhibition of the enzyme is associated with modestly increased risks of cardiovascular thrombotic events. Investigation of the physiology of COX-2 demonstrates a complex array of interlinked factors affecting its regulation and function. Efficient integration of data from the basic sciences and randomized and observational studies is necessary to fully understand the consequences of COX-2 inhibition and thereby provide guidance for the safe use of COX-2-inhibiting drugs.

Original languageEnglish
Pages (from-to)296-302
Number of pages7
JournalCurrent Cardiovascular Risk Reports
Volume1
Issue number4
DOIs
Publication statusPublished - 2007
Externally publishedYes

Fingerprint

Non-Steroidal Anti-Inflammatory Agents
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Observational Studies
Enzymes
Pharmaceutical Preparations

Cite this

McGettigan, Patricia ; Henry, David. / COX-2, NSAIDs, and cardiovascular risk. In: Current Cardiovascular Risk Reports. 2007 ; Vol. 1, No. 4. pp. 296-302.
@article{f19ebde9651e4ebe853e76aee7e5c433,
title = "COX-2, NSAIDs, and cardiovascular risk",
abstract = "Clinical studies of selective and nonselective inhibitors of cyclooxygenase-2 (COX-2) provide evidence that inhibition of the enzyme is associated with modestly increased risks of cardiovascular thrombotic events. Investigation of the physiology of COX-2 demonstrates a complex array of interlinked factors affecting its regulation and function. Efficient integration of data from the basic sciences and randomized and observational studies is necessary to fully understand the consequences of COX-2 inhibition and thereby provide guidance for the safe use of COX-2-inhibiting drugs.",
author = "Patricia McGettigan and David Henry",
year = "2007",
doi = "10.1007/s12170-007-0048-y",
language = "English",
volume = "1",
pages = "296--302",
journal = "Current Cardiovascular Risk Reports",
issn = "1932-9520",
publisher = "Current Medicine Group",
number = "4",

}

COX-2, NSAIDs, and cardiovascular risk. / McGettigan, Patricia; Henry, David.

In: Current Cardiovascular Risk Reports, Vol. 1, No. 4, 2007, p. 296-302.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - COX-2, NSAIDs, and cardiovascular risk

AU - McGettigan, Patricia

AU - Henry, David

PY - 2007

Y1 - 2007

N2 - Clinical studies of selective and nonselective inhibitors of cyclooxygenase-2 (COX-2) provide evidence that inhibition of the enzyme is associated with modestly increased risks of cardiovascular thrombotic events. Investigation of the physiology of COX-2 demonstrates a complex array of interlinked factors affecting its regulation and function. Efficient integration of data from the basic sciences and randomized and observational studies is necessary to fully understand the consequences of COX-2 inhibition and thereby provide guidance for the safe use of COX-2-inhibiting drugs.

AB - Clinical studies of selective and nonselective inhibitors of cyclooxygenase-2 (COX-2) provide evidence that inhibition of the enzyme is associated with modestly increased risks of cardiovascular thrombotic events. Investigation of the physiology of COX-2 demonstrates a complex array of interlinked factors affecting its regulation and function. Efficient integration of data from the basic sciences and randomized and observational studies is necessary to fully understand the consequences of COX-2 inhibition and thereby provide guidance for the safe use of COX-2-inhibiting drugs.

UR - http://www.scopus.com/inward/record.url?scp=84873491701&partnerID=8YFLogxK

U2 - 10.1007/s12170-007-0048-y

DO - 10.1007/s12170-007-0048-y

M3 - Article

VL - 1

SP - 296

EP - 302

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

SN - 1932-9520

IS - 4

ER -